ID   HAOX2_RAT               Reviewed;         353 AA.
AC   Q07523;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   29-MAY-2024, entry version 164.
DE   RecName: Full=2-Hydroxyacid oxidase 2;
DE            Short=HAOX2;
DE            EC=1.1.3.15 {ECO:0000305|PubMed:15683236, ECO:0000305|PubMed:3061453, ECO:0000305|PubMed:8508789};
DE   AltName: Full=(S)-2-hydroxy-acid oxidase, peroxisomal;
DE   AltName: Full=Long chain alpha-hydroxy acid oxidase {ECO:0000303|PubMed:1939137};
DE   AltName: Full=Long-chain L-2-hydroxy acid oxidase {ECO:0000303|PubMed:15683236, ECO:0000303|PubMed:8508789};
DE            Short=LCHAO {ECO:0000303|PubMed:15683236};
GN   Name=Hao2; Synonyms=Hao3, Haox2;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, SUBUNIT, COFACTOR,
RP   CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RC   STRAIN=Wistar; TISSUE=Kidney;
RX   PubMed=8508789; DOI=10.1111/j.1432-1033.1993.tb17891.x;
RA   Belmouden A., Le K.H.D., Lederer F., Garchon H.J.;
RT   "Molecular cloning and nucleotide sequence of cDNA encoding rat kidney
RT   long-chain L-2-hydroxy acid oxidase. Expression of the catalytically active
RT   recombinant protein as a chimaera.";
RL   Eur. J. Biochem. 214:17-25(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   PROTEIN SEQUENCE OF 2-353.
RC   TISSUE=Kidney;
RX   PubMed=1939137; DOI=10.1016/s0021-9258(18)54791-8;
RA   Le K.H.D., Lederer F.;
RT   "Amino acid sequence of long chain alpha-hydroxy acid oxidase from rat
RT   kidney, a member of the family of FMN-dependent alpha-hydroxy acid-
RT   oxidizing enzymes.";
RL   J. Biol. Chem. 266:20877-20881(1991).
RN   [4]
RP   PROTEIN SEQUENCE OF 2-41, FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL
RP   PROPERTIES, AND COFACTOR.
RX   PubMed=3061453; DOI=10.1021/bi00419a029;
RA   Urban P., Chirat I., Lederer F.;
RT   "Rat kidney L-2-hydroxyacid oxidase. Structural and mechanistic comparison
RT   with flavocytochrome b2 from baker's yeast.";
RL   Biochemistry 27:7365-7371(1988).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-133, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [6] {ECO:0007744|PDB:1TB3}
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) IN COMPLEX WITH FMN, FUNCTION,
RP   CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, COFACTOR, SUBUNIT, AND
RP   ACTIVE SITE.
RX   PubMed=15683236; DOI=10.1021/bi048616e;
RA   Cunane L.M., Barton J.D., Chen Z.-W., Le K.H.D., Amar D., Lederer F.,
RA   Mathews F.S.;
RT   "Crystal structure analysis of recombinant rat kidney long chain hydroxy
RT   acid oxidase.";
RL   Biochemistry 44:1521-1531(2005).
RN   [7] {ECO:0007744|PDB:3SGZ}
RP   X-RAY CRYSTALLOGRAPHY (1.35 ANGSTROMS) OF 2-353 IN COMPLEX WITH
RP   4-CARBOXY-5-[(4-CHLOROPHENYL)SULFANYL]-1,2,3-THIADIAZOLE INHIBITOR AND FMN,
RP   COFACTOR, AND ACTIVITY REGULATION.
RX   PubMed=22342614; DOI=10.1016/j.biochi.2012.02.003;
RA   Chen Z.W., Vignaud C., Jaafar A., Levy B., Gueritte F., Guenard D.,
RA   Lederer F., Mathews F.S.;
RT   "High resolution crystal structure of rat long chain hydroxy acid oxidase
RT   in complex with the inhibitor 4-carboxy-5-[(4-chlorophenyl)sulfanyl]-1,2,3-
RT   thiadiazole. Implications for inhibitor specificity and drug design.";
RL   Biochimie 94:1172-1179(2012).
CC   -!- FUNCTION: Oxidase that catalyzes the oxidation of medium and long chain
CC       hydroxyacids such as 2-hydroxyhexadecanoate, 2-hydroxyoctanoate, 2-
CC       hydroxyhexanoate and 2-hydroxybutanoate, to the correspondong 2-
CC       oxoacids (PubMed:15683236, PubMed:3061453, PubMed:8508789). Its role in
CC       the oxidation of 2-hydroxy fatty acids may contribute to the general
CC       pathway of fatty acid alpha-oxidation (By similarity). Can also use
CC       mandelate as substrate (PubMed:3061453). Active in vitro with the
CC       artificial electron acceptor 2,6-dichlorophenolindophenol (DCIP), but
CC       O2 is believed to be the physiological electron acceptor, leading to
CC       the production of H2O2 (PubMed:15683236, PubMed:3061453,
CC       PubMed:8508789). {ECO:0000250|UniProtKB:Q9NYQ3,
CC       ECO:0000269|PubMed:15683236, ECO:0000269|PubMed:3061453,
CC       ECO:0000269|PubMed:8508789}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a (2S)-2-hydroxycarboxylate + O2 = a 2-oxocarboxylate + H2O2;
CC         Xref=Rhea:RHEA:16789, ChEBI:CHEBI:15379, ChEBI:CHEBI:16240,
CC         ChEBI:CHEBI:35179, ChEBI:CHEBI:58123; EC=1.1.3.15;
CC         Evidence={ECO:0000305|PubMed:15683236, ECO:0000305|PubMed:3061453,
CC         ECO:0000305|PubMed:8508789};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:16790;
CC         Evidence={ECO:0000305|PubMed:15683236, ECO:0000305|PubMed:3061453,
CC         ECO:0000305|PubMed:8508789};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2-hydroxyoctanoate + O2 = 2-oxooctanoate + H2O2;
CC         Xref=Rhea:RHEA:67940, ChEBI:CHEBI:15379, ChEBI:CHEBI:16240,
CC         ChEBI:CHEBI:133514, ChEBI:CHEBI:176689;
CC         Evidence={ECO:0000305|PubMed:15683236};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:67941;
CC         Evidence={ECO:0000305|PubMed:15683236};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2-hydroxyhexadecanoate + O2 = 2-oxohexadecanoate + H2O2;
CC         Xref=Rhea:RHEA:67944, ChEBI:CHEBI:15379, ChEBI:CHEBI:16240,
CC         ChEBI:CHEBI:65097, ChEBI:CHEBI:176593;
CC         Evidence={ECO:0000305|PubMed:15683236};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:67945;
CC         Evidence={ECO:0000305|PubMed:15683236};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2-hydroxyhexanoate + O2 = 2-oxohexanoate + H2O2;
CC         Xref=Rhea:RHEA:69372, ChEBI:CHEBI:15379, ChEBI:CHEBI:16240,
CC         ChEBI:CHEBI:35177, ChEBI:CHEBI:133738;
CC         Evidence={ECO:0000305|PubMed:3061453};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:69373;
CC         Evidence={ECO:0000305|PubMed:3061453};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=mandelate + O2 = H2O2 + phenylglyoxylate;
CC         Xref=Rhea:RHEA:68968, ChEBI:CHEBI:15379, ChEBI:CHEBI:16240,
CC         ChEBI:CHEBI:25147, ChEBI:CHEBI:36656;
CC         Evidence={ECO:0000305|PubMed:3061453};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:68969;
CC         Evidence={ECO:0000305|PubMed:3061453};
CC   -!- COFACTOR:
CC       Name=FMN; Xref=ChEBI:CHEBI:58210;
CC         Evidence={ECO:0000269|PubMed:15683236, ECO:0000269|PubMed:22342614,
CC         ECO:0000269|PubMed:3061453, ECO:0000269|PubMed:8508789};
CC       Note=Binds 1 FMN per subunit. {ECO:0000269|PubMed:15683236,
CC       ECO:0000269|PubMed:22342614, ECO:0000269|PubMed:3061453};
CC   -!- ACTIVITY REGULATION: Is inhibited in vitro by CCPST (4-carboxy-5-(4-
CC       chlorophenyl)sulfanyl-1,2,3-thiadiazole).
CC       {ECO:0000269|PubMed:22342614}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.046 mM for L-2-hydroxyoctanoate (with DCIP as electron acceptor)
CC         {ECO:0000269|PubMed:15683236};
CC         KM=1.36 mM for L-2-hydroxyhexadecanoate (with DCIP as electron
CC         acceptor) {ECO:0000269|PubMed:15683236};
CC         KM=0.69 mM for DL-2-hydroxybutanoate (with DCIP as electron acceptor)
CC         {ECO:0000269|PubMed:8508789};
CC         KM=0.6 mM for L-2-hydroxybutanoate (with DCIP as electron acceptor)
CC         {ECO:0000269|PubMed:3061453};
CC         KM=0.25 mM for L-2-hydroxyhexanoate (with DCIP as electron acceptor)
CC         {ECO:0000269|PubMed:3061453};
CC         KM=0.8 mM for L-mandelate (with DCIP as electron acceptor)
CC         {ECO:0000269|PubMed:3061453};
CC         Vmax=12 umol/min/mg enzyme with 2-hydroxybutanoate as substrate and
CC         DCIP as electron acceptor {ECO:0000269|PubMed:3061453};
CC         Vmax=5.8 umol/min/mg enzyme with 2-hydroxyhexanoate as substrate and
CC         DCIP as electron acceptor {ECO:0000269|PubMed:3061453};
CC         Vmax=21 umol/min/mg enzyme with L-mandelate as substrate and DCIP as
CC         electron acceptor {ECO:0000269|PubMed:3061453};
CC         Note=kcat is 0.99 sec(-1) for the oxidation of L-2-hydroxyoctanoate
CC         with DCIP instead of O2 as electron acceptor. kcat is 0.34 sec(-1)
CC         for the oxidation of L-2-hydroxyhexadecanoate with DCIP instead of O2
CC         as electron acceptor (PubMed:15683236). kcat is 1.66 sec(-1) for the
CC         oxidation of DL-2-hydroxybutanoate with DCIP instead of O2 as
CC         electron acceptor (PubMed:8508789). {ECO:0000269|PubMed:15683236,
CC         ECO:0000269|PubMed:8508789};
CC   -!- SUBUNIT: Homotetramer (PubMed:8508789). Could also form homooctamer.
CC       {ECO:0000269|PubMed:15683236, ECO:0000269|PubMed:8508789}.
CC   -!- SUBCELLULAR LOCATION: Peroxisome.
CC   -!- TISSUE SPECIFICITY: Expressed in kidney. {ECO:0000269|PubMed:1939137,
CC       ECO:0000269|PubMed:8508789}.
CC   -!- SIMILARITY: Belongs to the FMN-dependent alpha-hydroxy acid
CC       dehydrogenase family. {ECO:0000255|PROSITE-ProRule:PRU00683}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X67156; CAA47629.1; -; mRNA.
DR   EMBL; BC078781; AAH78781.1; -; mRNA.
DR   PIR; S33322; S33322.
DR   RefSeq; NP_114471.1; NM_032082.2.
DR   PDB; 1TB3; X-ray; 2.30 A; A/B/C/D/E/F/G/H=2-353.
DR   PDB; 3SGZ; X-ray; 1.35 A; A/B/C=2-353.
DR   PDBsum; 1TB3; -.
DR   PDBsum; 3SGZ; -.
DR   AlphaFoldDB; Q07523; -.
DR   SMR; Q07523; -.
DR   IntAct; Q07523; 1.
DR   STRING; 10116.ENSRNOP00000074018; -.
DR   BindingDB; Q07523; -.
DR   ChEMBL; CHEMBL2021745; -.
DR   iPTMnet; Q07523; -.
DR   PhosphoSitePlus; Q07523; -.
DR   PaxDb; 10116-ENSRNOP00000040223; -.
DR   Ensembl; ENSRNOT00000046942.3; ENSRNOP00000040223.1; ENSRNOG00000019470.7.
DR   Ensembl; ENSRNOT00055056753; ENSRNOP00055046857; ENSRNOG00055032816.
DR   Ensembl; ENSRNOT00060023703; ENSRNOP00060018855; ENSRNOG00060013867.
DR   Ensembl; ENSRNOT00065053630; ENSRNOP00065044078; ENSRNOG00065031098.
DR   GeneID; 84029; -.
DR   KEGG; rno:84029; -.
DR   UCSC; RGD:70972; rat.
DR   AGR; RGD:70972; -.
DR   CTD; 51179; -.
DR   RGD; 70972; Hao2.
DR   eggNOG; KOG0538; Eukaryota.
DR   GeneTree; ENSGT00390000018717; -.
DR   HOGENOM; CLU_020639_6_1_1; -.
DR   InParanoid; Q07523; -.
DR   OMA; WADFQYE; -.
DR   OrthoDB; 276514at2759; -.
DR   PhylomeDB; Q07523; -.
DR   TreeFam; TF313363; -.
DR   BRENDA; 1.1.3.15; 5301.
DR   Reactome; R-RNO-390918; Peroxisomal lipid metabolism.
DR   Reactome; R-RNO-9033241; Peroxisomal protein import.
DR   SABIO-RK; Q07523; -.
DR   EvolutionaryTrace; Q07523; -.
DR   PRO; PR:Q07523; -.
DR   Proteomes; UP000002494; Chromosome 2.
DR   Bgee; ENSRNOG00000019470; Expressed in adult mammalian kidney and 15 other cell types or tissues.
DR   ExpressionAtlas; Q07523; baseline and differential.
DR   GO; GO:0005782; C:peroxisomal matrix; ISO:RGD.
DR   GO; GO:0005777; C:peroxisome; IDA:HGNC-UCL.
DR   GO; GO:0003973; F:(S)-2-hydroxy-acid oxidase activity; IDA:RGD.
DR   GO; GO:0010181; F:FMN binding; IDA:RGD.
DR   GO; GO:0042802; F:identical protein binding; IPI:RGD.
DR   GO; GO:0001561; P:fatty acid alpha-oxidation; IBA:GO_Central.
DR   GO; GO:0019395; P:fatty acid oxidation; ISO:RGD.
DR   GO; GO:0018924; P:mandelate metabolic process; IDA:RGD.
DR   CDD; cd02809; alpha_hydroxyacid_oxid_FMN; 1.
DR   Gene3D; 3.20.20.70; Aldolase class I; 1.
DR   InterPro; IPR013785; Aldolase_TIM.
DR   InterPro; IPR012133; Alpha-hydoxy_acid_DH_FMN.
DR   InterPro; IPR000262; FMN-dep_DH.
DR   InterPro; IPR037396; FMN_HAD.
DR   InterPro; IPR008259; FMN_hydac_DH_AS.
DR   PANTHER; PTHR10578:SF139; 2-HYDROXYACID OXIDASE 2; 1.
DR   PANTHER; PTHR10578; S -2-HYDROXY-ACID OXIDASE-RELATED; 1.
DR   Pfam; PF01070; FMN_dh; 1.
DR   PIRSF; PIRSF000138; Al-hdrx_acd_dh; 1.
DR   SUPFAM; SSF51395; FMN-linked oxidoreductases; 1.
DR   PROSITE; PS00557; FMN_HYDROXY_ACID_DH_1; 1.
DR   PROSITE; PS51349; FMN_HYDROXY_ACID_DH_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Direct protein sequencing; Fatty acid metabolism;
KW   Flavoprotein; FMN; Lipid metabolism; Oxidoreductase; Peroxisome;
KW   Phosphoprotein; Reference proteome.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:1939137,
FT                   ECO:0000269|PubMed:3061453"
FT   CHAIN           2..353
FT                   /note="2-Hydroxyacid oxidase 2"
FT                   /id="PRO_0000206322"
FT   DOMAIN          2..353
FT                   /note="FMN hydroxy acid dehydrogenase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00683"
FT   MOTIF           351..353
FT                   /note="Microbody targeting signal"
FT                   /evidence="ECO:0000255"
FT   ACT_SITE        248
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00683,
FT                   ECO:0000305|PubMed:15683236"
FT   BINDING         77..79
FT                   /ligand="FMN"
FT                   /ligand_id="ChEBI:CHEBI:58210"
FT                   /evidence="ECO:0000269|PubMed:15683236,
FT                   ECO:0000269|PubMed:22342614, ECO:0007744|PDB:1TB3,
FT                   ECO:0007744|PDB:3SGZ"
FT   BINDING         106
FT                   /ligand="FMN"
FT                   /ligand_id="ChEBI:CHEBI:58210"
FT                   /evidence="ECO:0000269|PubMed:15683236,
FT                   ECO:0000269|PubMed:22342614, ECO:0007744|PDB:1TB3,
FT                   ECO:0007744|PDB:3SGZ"
FT   BINDING         128
FT                   /ligand="FMN"
FT                   /ligand_id="ChEBI:CHEBI:58210"
FT                   /evidence="ECO:0000269|PubMed:15683236,
FT                   ECO:0000269|PubMed:22342614, ECO:0007744|PDB:1TB3,
FT                   ECO:0007744|PDB:3SGZ"
FT   BINDING         130
FT                   /ligand="a 2-oxocarboxylate"
FT                   /ligand_id="ChEBI:CHEBI:35179"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00683"
FT   BINDING         156
FT                   /ligand="FMN"
FT                   /ligand_id="ChEBI:CHEBI:58210"
FT                   /evidence="ECO:0000269|PubMed:15683236,
FT                   ECO:0000269|PubMed:22342614, ECO:0007744|PDB:1TB3,
FT                   ECO:0007744|PDB:3SGZ"
FT   BINDING         165
FT                   /ligand="a 2-oxocarboxylate"
FT                   /ligand_id="ChEBI:CHEBI:35179"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00683"
FT   BINDING         224
FT                   /ligand="FMN"
FT                   /ligand_id="ChEBI:CHEBI:58210"
FT                   /evidence="ECO:0000269|PubMed:15683236,
FT                   ECO:0000269|PubMed:22342614, ECO:0007744|PDB:1TB3,
FT                   ECO:0007744|PDB:3SGZ"
FT   BINDING         251
FT                   /ligand="a 2-oxocarboxylate"
FT                   /ligand_id="ChEBI:CHEBI:35179"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00683"
FT   BINDING         279..283
FT                   /ligand="FMN"
FT                   /ligand_id="ChEBI:CHEBI:58210"
FT                   /evidence="ECO:0000269|PubMed:15683236,
FT                   ECO:0000269|PubMed:22342614, ECO:0007744|PDB:1TB3,
FT                   ECO:0007744|PDB:3SGZ"
FT   BINDING         302..303
FT                   /ligand="FMN"
FT                   /ligand_id="ChEBI:CHEBI:58210"
FT                   /evidence="ECO:0000269|PubMed:15683236,
FT                   ECO:0000269|PubMed:22342614, ECO:0007744|PDB:1TB3,
FT                   ECO:0007744|PDB:3SGZ"
FT   MOD_RES         133
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   HELIX           6..15
FT                   /evidence="ECO:0007829|PDB:3SGZ"
FT   HELIX           19..26
FT                   /evidence="ECO:0007829|PDB:3SGZ"
FT   HELIX           33..43
FT                   /evidence="ECO:0007829|PDB:3SGZ"
FT   STRAND          62..64
FT                   /evidence="ECO:0007829|PDB:3SGZ"
FT   STRAND          67..75
FT                   /evidence="ECO:0007829|PDB:3SGZ"
FT   HELIX           81..83
FT                   /evidence="ECO:0007829|PDB:3SGZ"
FT   HELIX           88..99
FT                   /evidence="ECO:0007829|PDB:3SGZ"
FT   STRAND          102..105
FT                   /evidence="ECO:0007829|PDB:3SGZ"
FT   HELIX           113..119
FT                   /evidence="ECO:0007829|PDB:3SGZ"
FT   STRAND          124..128
FT                   /evidence="ECO:0007829|PDB:3SGZ"
FT   HELIX           135..147
FT                   /evidence="ECO:0007829|PDB:3SGZ"
FT   STRAND          153..156
FT                   /evidence="ECO:0007829|PDB:3SGZ"
FT   HELIX           166..174
FT                   /evidence="ECO:0007829|PDB:3SGZ"
FT   HELIX           177..180
FT                   /evidence="ECO:0007829|PDB:3SGZ"
FT   HELIX           207..216
FT                   /evidence="ECO:0007829|PDB:3SGZ"
FT   STRAND          221..226
FT                   /evidence="ECO:0007829|PDB:3SGZ"
FT   HELIX           229..237
FT                   /evidence="ECO:0007829|PDB:3SGZ"
FT   STRAND          241..245
FT                   /evidence="ECO:0007829|PDB:3SGZ"
FT   HELIX           248..250
FT                   /evidence="ECO:0007829|PDB:3SGZ"
FT   HELIX           259..270
FT                   /evidence="ECO:0007829|PDB:3SGZ"
FT   STRAND          273..281
FT                   /evidence="ECO:0007829|PDB:3SGZ"
FT   HELIX           285..293
FT                   /evidence="ECO:0007829|PDB:3SGZ"
FT   STRAND          297..302
FT                   /evidence="ECO:0007829|PDB:3SGZ"
FT   HELIX           303..335
FT                   /evidence="ECO:0007829|PDB:3SGZ"
FT   HELIX           340..342
FT                   /evidence="ECO:0007829|PDB:3SGZ"
FT   HELIX           345..347
FT                   /evidence="ECO:0007829|PDB:3SGZ"
FT   STRAND          348..350
FT                   /evidence="ECO:0007829|PDB:3SGZ"
SQ   SEQUENCE   353 AA;  39201 MW;  A2FDD4BF34E269E5 CRC64;
     MPLVCLADFK AHAQKQLSKT SWDFIEGEAD DGITYSENIA AFKRIRLRPR YLRDMSKVDT
     RTTIQGQEIS APICISPTAF HSIAWPDGEK STARAAQEAN ICYVISSYAS YSLEDIVAAA
     PEGFRWFQLY MKSDWDFNKQ MVQRAEALGF KALVITIDTP VLGNRRRDKR NQLNLEANIL
     LKDLRALKEE KPTQSVPVSF PKASFCWNDL SLLQSITRLP IILKGILTKE DAELAMKHNV
     QGIVVSNHGG RQLDEVSASI DALREVVAAV KGKIEVYMDG GVRTGTDVLK ALALGARCIF
     LGRPILWGLA CKGEDGVKEV LDILTAELHR CMTLSGCQSV AEISPDLIQF SRL
//
